<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83826">
  <stage>Registered</stage>
  <submitdate>17/04/2009</submitdate>
  <approvaldate>19/05/2009</approvaldate>
  <actrnumber>ACTRN12609000300279</actrnumber>
  <trial_identification>
    <studytitle>Development of valid immunoassay methods for Luteinising Hormone (LH) in urine.</studytitle>
    <scientifictitle>Detection of exogenous Luteinising Hormone (LH) as a sports doping agent (with and without supression of endogenous LH) in urine of healthy adult male volunteers. An open label, parallel group study.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Detection of LH in healthy males, as a sports doping agent.</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Normal metabolism and endocrine development and function</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>a) 2 participants will receive 200mg nandrolone decanoate by  intramuscular (IM) injection 4 days prior to receiving an intravenous infusion (IV) of 2400iu recombinant luteinising hormone (rLH). 
b) 2 particpants will receive in IV infusion of rLH only.
All 4 particpants will have blood samples taken prior to commencing the rLH infusion (at 0 minutes) then again at 1,2,3,4,6 and 8 hours.  A further blood sample will be taken at 24 hours.</interventions>
    <comparator>The group receiving nandrolone will be compared with the non nandrolone group. The baseline samples of each particpant will be compared with subsequent samples provided.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A demonstrated rise in urinary rLH (detected by immunoassay), samples of which will be used to develop valid immunoassay measurements for use in sports anti-doping testing.</outcome>
      <timepoint>All urine passed between  0 and 4 hours, 4 and 8 hours and 8 to 24 hours will be collected as 3 seperate collections.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Serum samples for LH and testosterone levels.</outcome>
      <timepoint>All 4 particpants will have blood samples taken prior to commencing the rLH infusion (at 0 minutes) then again at 1,2,3,4,6 and 8 hours.  A further blood sample will be taken at 24 hours. All samples will be stored for later analysis.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy males aged 18 to 65.
Not taking any form of androgens.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of anabolic steroid use.
Poor health.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence>Non randomised study.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>4/05/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Sydney South Western Area Health Service (SSWAHS)</primarysponsorname>
    <primarysponsoraddress>Concord Repatriation General Hospital, Hospital Raod, Concord, NSW 2139</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>World Anti-Doping Agency (WADA)</fundingname>
      <fundingaddress>Stock Exchange Tower, 800 Victoria Place (Suite 1700), PO Box 120, Montreal</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Australian Sports Drug Testing Laboratory (ASDTL)</othercollaboratorname>
      <othercollaboratoraddress>1 Suakin Street, Pymble, NSW 2073</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to develop effective testing methods for the detection of injected recombinanat luteinising hormone (rLH) excreted in urine. The blood and urine samples taken from male volunteers in this study will be used to develop robust testing for the illicit use of rLH in elite athletes for performance enhancement. Four healthy male adults will be recruited. Two will receive an intramuscular (IM) injection of nanadrolone 200mg, 4 days prior to an intravenous (IV) infusion of 2400iu rLH. Nandrolone is a synthetic androgen which will act to temporarily supress the bodys own LH production.
The other two participants will receive an IV infusion of rLH 2400iu ( no nandrolone).
Samples of urine will be collected from all participants at 0 to 4 hours, 4 to 8 hours and 8 to 24 hours. Blood samples will be collected at baseline, 1, 2, 3, 4, 6, 8 and 24 hous following rLH infusion.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Concord Hospital Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Concord Hospital, Hospital Road, Concord, NSW 2139</ethicaddress>
      <ethicapprovaldate>23/10/2008</ethicapprovaldate>
      <hrec>08/CRGH/106  CH62/6/2008-82</hrec>
      <ethicsubmitdate>30/06/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>D J Handelsman</name>
      <address>Anzac Research Institute, Hospital Road, Concord NSW 2139</address>
      <phone>00612 9767 7222</phone>
      <fax>00612 9767 7221</fax>
      <email>djh@anzac.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>D J Handelsman</name>
      <address>Anzac Research Institute, Hospital Road, Concord, NSW 2139</address>
      <phone>00612 9767 222</phone>
      <fax>00612 9767 7221</fax>
      <email>djh@anzac.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Amanda Idan</name>
      <address>Department of Andrology, Bdg 22, Concord Hospital, Hospital Road, Concord 2139</address>
      <phone>00612 9767 7222</phone>
      <fax>00612 9767 7221</fax>
      <email>aidan@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>